Epidermal growth factor receptor tyrosine kinase inhibitors View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2004-05-11

AUTHORS

M Ranson

ABSTRACT

Activation of the epidermal growth factor receptor (EGFR) has been linked to tumour proliferation, invasion, metastasis and angiogenesis in epithelial tumours. Inhibitors of the EGFR have emerged as promising anticancer agents and two main approaches have been developed, humanised monoclonal antibodies and tyrosine kinase inhibitors. This review discusses the current status of EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have entered clinical development. EGFR-TKIs are generally well tolerated and can sometimes produce impressive tumour regression in patients with advanced non-small-cell lung cancer. However, highly predictive or surrogate markers of activity have not been identified and there remains a need for translational research in their future development. More... »

PAGES

2250-2255

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6601873

DOI

http://dx.doi.org/10.1038/sj.bjc.6601873

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021715784

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15150574


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ErbB Receptors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein-Tyrosine Kinases", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, M20 4BX, Manchester, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, M20 4BX, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ranson", 
        "givenName": "M", 
        "id": "sg:person.01124372241.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124372241.32"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.onc.1206388", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004564925", 
          "https://doi.org/10.1038/sj.onc.1206388"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-05-11", 
    "datePublishedReg": "2004-05-11", 
    "description": "Activation of the epidermal growth factor receptor (EGFR) has been linked to tumour proliferation, invasion, metastasis and angiogenesis in epithelial tumours. Inhibitors of the EGFR have emerged as promising anticancer agents and two main approaches have been developed, humanised monoclonal antibodies and tyrosine kinase inhibitors. This review discusses the current status of EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have entered clinical development. EGFR-TKIs are generally well tolerated and can sometimes produce impressive tumour regression in patients with advanced non-small-cell lung cancer. However, highly predictive or surrogate markers of activity have not been identified and there remains a need for translational research in their future development.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6601873", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "90"
      }
    ], 
    "keywords": [
      "tyrosine kinase inhibitors", 
      "epidermal growth factor receptor", 
      "kinase inhibitors", 
      "epidermal growth factor receptor tyrosine kinase inhibitors", 
      "growth factor receptor tyrosine kinase inhibitors", 
      "receptor tyrosine kinase inhibitors", 
      "EGFR tyrosine kinase inhibitors", 
      "cell lung cancer", 
      "impressive tumor regression", 
      "growth factor receptor", 
      "lung cancer", 
      "tumor regression", 
      "surrogate marker", 
      "epithelial tumors", 
      "clinical development", 
      "promising anticancer agent", 
      "monoclonal antibodies", 
      "factor receptor", 
      "translational research", 
      "anticancer agents", 
      "inhibitors", 
      "patients", 
      "metastasis", 
      "tumors", 
      "cancer", 
      "receptors", 
      "antibodies", 
      "angiogenesis", 
      "current status", 
      "invasion", 
      "proliferation", 
      "markers", 
      "activation", 
      "status", 
      "review", 
      "regression", 
      "agents", 
      "development", 
      "activity", 
      "need", 
      "future development", 
      "research", 
      "approach", 
      "main approaches"
    ], 
    "name": "Epidermal growth factor receptor tyrosine kinase inhibitors", 
    "pagination": "2250-2255", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021715784"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6601873"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15150574"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6601873", 
      "https://app.dimensions.ai/details/publication/pub.1021715784"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_393.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6601873"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601873'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601873'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601873'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601873'


 

This table displays all metadata directly associated to this object as RDF triples.

145 TRIPLES      21 PREDICATES      79 URIs      70 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6601873 schema:about N032a5feede50469ea5f0b8b897830523
2 N2b6e8a4951b242598f460e3874542e53
3 N394dd7883ede4854a08ac7079878a155
4 N3a9ce456f5714794a755dfdd607a12d7
5 N46688dbcb61d4ea595245c00a13531d3
6 N8c6f847166a44e0792376b0030e73fe0
7 N9c2c60fb0c0a493ba027a4cc12e7c32f
8 Na132f081c9314b0f932d2fedc0114310
9 Nf08d099b90804e0ba5c51c205e7b5209
10 anzsrc-for:11
11 anzsrc-for:1112
12 schema:author Neb2755e64080429d98a6392ddcd7b752
13 schema:citation sg:pub.10.1038/sj.onc.1206388
14 schema:datePublished 2004-05-11
15 schema:datePublishedReg 2004-05-11
16 schema:description Activation of the epidermal growth factor receptor (EGFR) has been linked to tumour proliferation, invasion, metastasis and angiogenesis in epithelial tumours. Inhibitors of the EGFR have emerged as promising anticancer agents and two main approaches have been developed, humanised monoclonal antibodies and tyrosine kinase inhibitors. This review discusses the current status of EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have entered clinical development. EGFR-TKIs are generally well tolerated and can sometimes produce impressive tumour regression in patients with advanced non-small-cell lung cancer. However, highly predictive or surrogate markers of activity have not been identified and there remains a need for translational research in their future development.
17 schema:genre article
18 schema:isAccessibleForFree true
19 schema:isPartOf Ne3fbf83075854fe988c862eb188c1d7d
20 Nf7833bc5ed674d828766bb00492a3187
21 sg:journal.1017082
22 schema:keywords EGFR tyrosine kinase inhibitors
23 activation
24 activity
25 agents
26 angiogenesis
27 antibodies
28 anticancer agents
29 approach
30 cancer
31 cell lung cancer
32 clinical development
33 current status
34 development
35 epidermal growth factor receptor
36 epidermal growth factor receptor tyrosine kinase inhibitors
37 epithelial tumors
38 factor receptor
39 future development
40 growth factor receptor
41 growth factor receptor tyrosine kinase inhibitors
42 impressive tumor regression
43 inhibitors
44 invasion
45 kinase inhibitors
46 lung cancer
47 main approaches
48 markers
49 metastasis
50 monoclonal antibodies
51 need
52 patients
53 proliferation
54 promising anticancer agent
55 receptor tyrosine kinase inhibitors
56 receptors
57 regression
58 research
59 review
60 status
61 surrogate marker
62 translational research
63 tumor regression
64 tumors
65 tyrosine kinase inhibitors
66 schema:name Epidermal growth factor receptor tyrosine kinase inhibitors
67 schema:pagination 2250-2255
68 schema:productId N1494fbb451e04570969735e4f1f31730
69 Nbb85bb85f07f470d9aa125a2b22f9030
70 Ncd16a3d1698841408e74959053e5dada
71 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021715784
72 https://doi.org/10.1038/sj.bjc.6601873
73 schema:sdDatePublished 2022-10-01T06:32
74 schema:sdLicense https://scigraph.springernature.com/explorer/license/
75 schema:sdPublisher N70392846499c418cbd06363feaadd77d
76 schema:url https://doi.org/10.1038/sj.bjc.6601873
77 sgo:license sg:explorer/license/
78 sgo:sdDataset articles
79 rdf:type schema:ScholarlyArticle
80 N032a5feede50469ea5f0b8b897830523 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Protein-Tyrosine Kinases
82 rdf:type schema:DefinedTerm
83 N1494fbb451e04570969735e4f1f31730 schema:name dimensions_id
84 schema:value pub.1021715784
85 rdf:type schema:PropertyValue
86 N2b6e8a4951b242598f460e3874542e53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Carcinoma, Non-Small-Cell Lung
88 rdf:type schema:DefinedTerm
89 N394dd7883ede4854a08ac7079878a155 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Lung Neoplasms
91 rdf:type schema:DefinedTerm
92 N3a9ce456f5714794a755dfdd607a12d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Humans
94 rdf:type schema:DefinedTerm
95 N46688dbcb61d4ea595245c00a13531d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Clinical Trials as Topic
97 rdf:type schema:DefinedTerm
98 N70392846499c418cbd06363feaadd77d schema:name Springer Nature - SN SciGraph project
99 rdf:type schema:Organization
100 N8c6f847166a44e0792376b0030e73fe0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name ErbB Receptors
102 rdf:type schema:DefinedTerm
103 N9c2c60fb0c0a493ba027a4cc12e7c32f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Antineoplastic Agents
105 rdf:type schema:DefinedTerm
106 Na132f081c9314b0f932d2fedc0114310 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Biomarkers, Tumor
108 rdf:type schema:DefinedTerm
109 Nbb85bb85f07f470d9aa125a2b22f9030 schema:name pubmed_id
110 schema:value 15150574
111 rdf:type schema:PropertyValue
112 Ncd16a3d1698841408e74959053e5dada schema:name doi
113 schema:value 10.1038/sj.bjc.6601873
114 rdf:type schema:PropertyValue
115 Ne3fbf83075854fe988c862eb188c1d7d schema:volumeNumber 90
116 rdf:type schema:PublicationVolume
117 Neb2755e64080429d98a6392ddcd7b752 rdf:first sg:person.01124372241.32
118 rdf:rest rdf:nil
119 Nf08d099b90804e0ba5c51c205e7b5209 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Antibodies, Monoclonal
121 rdf:type schema:DefinedTerm
122 Nf7833bc5ed674d828766bb00492a3187 schema:issueNumber 12
123 rdf:type schema:PublicationIssue
124 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
125 schema:name Medical and Health Sciences
126 rdf:type schema:DefinedTerm
127 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
128 schema:name Oncology and Carcinogenesis
129 rdf:type schema:DefinedTerm
130 sg:journal.1017082 schema:issn 0007-0920
131 1532-1827
132 schema:name British Journal of Cancer
133 schema:publisher Springer Nature
134 rdf:type schema:Periodical
135 sg:person.01124372241.32 schema:affiliation grid-institutes:None
136 schema:familyName Ranson
137 schema:givenName M
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124372241.32
139 rdf:type schema:Person
140 sg:pub.10.1038/sj.onc.1206388 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004564925
141 https://doi.org/10.1038/sj.onc.1206388
142 rdf:type schema:CreativeWork
143 grid-institutes:None schema:alternateName Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, M20 4BX, Manchester, UK
144 schema:name Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, M20 4BX, Manchester, UK
145 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...